αV integrin receptor antagonists

A compound of the Formula (I)

• or a pharmaceutically acceptable salt thereof, wherein:
• X is selected from the group consisting of
• each R1 is independently hydrogen or C1-3 alkyl and each non-aromatic ring carbon atom is unsubstituted or independently substituted with one or two R2 substituents and each aromatic ring carbon atom is unsubstituted or independently substituted with one R2 substituent selected from the group consisting of
• C1-8 alkyl, C3-8 cycloalkyl,
• C3-8 cycloheteroalkyl, C3-8 cycloalkyl-C1-6 alkyl,
• C3-8 cycloheteroalkyl-C1-6 alkyl, aryl, aryl-C1-6 alkyl,
• amino-C1-6 alkyl, C1-3 acylamino, C1-3 acylamino-C1-6 alkyl,
• amino, (C1-6 alkyl)1-2 amino, C3-6 cycloalkyl-C0-2 amino,
• (C1-6 alkyl)1-2 amino-C1-6 alkyl, C1-6 alkoxy, C1-4 alkoxy-C1-6 alkyl,
• hydroxycarbonyl, hydroxycarbonyl-C1-6 alkyl, C1-3 alkoxycarbonyl,
• C1-3 alkoxycarbonyl-C1-6 alkyl, hydroxy, hydroxy-C1-6 alkyl,
• nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy,
• C1-8 alkyl-S(O)0-2, (C1-8 alkyl)0-2 aminocarbonyl,
• C1-8 alkyloxycarbonylamino, (C1-8 alkyl)1-2 aminocarbonyloxy,
• (aryl)1-2 amino, aryl-C1-3 alkylsulfonylamino, and C1-8 alkylsulfonylamino;
• or two R2 substituents, when on the same non-aromatic carbon atom, are taken together with the carbon atom to which they are attached to form a carbonyl group;
• or two R2 substituents, together with the carbon atom to which they are attached, join to form a 3- to 6-membered saturated spiro-carbocyclic ring;
• R4 is aryl wherein the aryl group is selected from the group consisting of
• (1) phenyl,
• (2) naphthyl,
• (3) pyridyl,
• (4) furyl,
• (5) thienyl,
• (6) pyrrolyl,
• (7) oxazolyl,
• (8) thiazolyl,
• (9) imidazolyl,
• (10) pyrazolyl,
• (11) isoxazolyl,
• (12) isothiazolyl,
• (13) pyrimidinyl,
• (14) quinolyl,
• (15) isoquinolyl,
• (16) benzimidazolyl,
• (17) benzofuryl,
• (18) benzothienyl,
• (19) indolyl,
• (20) benzthiazolyl,
• (21) benzoxazolyl,
• (22) dihydrobenzofuryl,
• (23) benzo(1,3)dioxolanyl, and
• (24) benzo(1,4)dioxanyl;
• and mono, di, and tri-substituted aryl wherein the substituents are independently hydrogen, hydroxy, hydroxy-C1-6 alkyl, halogen, C1-8 alkyl, C3-8 cycloalkyl, aryl, aryl C1-3 alkyl, amino, amino C1-6 alkyl, C1-3 acylamino, C1-3 acylamino-C1-6 alkyl, C1-6 alkylamino, di(C1-6)alkylamino, C1-6 alkylamino-C1-6 alkyl, di(C1-6)alkylamino-C1-6 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylsulfinyl, C1-4 alkylsulfonyl, C1-4 alkoxy-C1-6 alkyl, hydroxycarbonyl, hydroxycarbonyl-C1-6 alkyl, C1-5 alkoxycarbonyl, C1-3 alkoxycarbonyl-C1-6 alkyl, C1-5 alkylcarbonyloxy, cyano, trifluoromethyl, 1,1,1-trifluoroethyl, trifluoromethoxy, trifluoroethoxy, or nitro;
• or two adjacent substituents together with the carbon atoms to which they are attached join to form a five- or six-membered saturated or unsaturated ring containing 1 or 2 heteroatoms selected from the group consisting of N, O, and S, whose ring carbon atoms may be substituted with oxo or C1-3 alkyl;
• and
• R3 is hydrogen or C1-3 alkyl.